YD Bio Limited Ordinary Shares
HealthcareNASDAQ:YDES · NASDAQ Global Select
+$0.02 today
Vol 0.01M · Avg 0.02M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
291.0%
avg 61.3%
ROIC
-43.4%
avg -16.1%
ROA
-60.3%
avg -8.4%
Analysis
ROE is currently the strongest return metric at 291.0% versus its period average of 61.3%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Benjamin Zhang | Chief Medical Officer & Director | — | — | 26 | $31,141.00 | 0.04% |
Ethan Shen | CEO & Chairman | — | — | 49 | $43.12M | 60.88% |
Edmund Hen | Chief Financial Officer | — | — | 52 | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A — |
| Revenue | N/A | N/A | N/A | N/A — |
| Net Income | N/A | N/A | N/A | N/A — |
| EBIT | N/A | N/A | N/A | N/A — |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Day One Biopharmaceuticals, Inc.
DAWN
$2.22B
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.61B
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.45B
Monte Rosa Therapeutics, Inc.
NASDAQ:GLUE
$1.19B
BlackRock Technology and Private Equity Term Trust
BTX
$1.05B
Theravance Biopharma, Inc.
NASDAQ:TBPH
$857.84M
Geron Corporation
NASDAQ:GERN
$737.75M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$722.58M
Prime Medicine, Inc.
NASDAQ:PRME
$501.21M
LENZ Therapeutics, Inc.
NASDAQ:LENZ
$212.27M
Who manages YDES?
YD Bio Limited Ordinary Shares (YDES) lists 3 active executives. The top listed executive is Benjamin Zhang, Chief Medical Officer & Director.
Are YDES insiders buying or selling?
Recent insider activity shows net buying of $0.42.
Explore More
Continue the stock analysis
Jump to another research area for this company.